Canadian cost data associated with treating overactive bladder is lacking

Dylan Viste; Carly Barton; Kevin Carlson; Richard Baverstock; R. Trafford Crump
University of Calgary, Calgary, AB, Canada

Acknowledgments: The authors would like to thank Ms. Loraine Toews from the University of Calgary’s Cumming School of Medicine’s Library for help with the systematic search of publication databases, as well as Ms. Sophie Hoye Pacholek and Ms. Jayhan Kherani for their assistance in preparing the manuscript.

Funding: This research was supported by the CUA-Astellas Research Grant Program funded by Astellas Pharma Canada, Inc. and jointly established by Astellas Pharma Canada, Inc. and the Canadian Urological Association.

Cite as: Viste D, Barton C, Carlson K, et al. Canadian cost data associated with treating overactive bladder is lacking. Can Urol Assoc J 2021 October 18; Epub ahead of print. http://dx.doi.org/10.5489/cuaj.7500

Published online October 18, 2021

Corresponding author: Dr. R. Trafford Crump, University of Calgary, Calgary, AB, Canada; tcrump@ucalgary.ca

***

Abstract

Introduction: Cost-effectiveness analysis forms an integral part of the approval process for new medical treatments in Canada, including drug and non-drug technologies. This study’s primary objective was to identify peer-reviewed studies that report Canadian-specific cost data for treating overactive bladder (OAB) based on the Canadian Urological Association (CUA) guidelines. A secondary objective was to identify studies that report cost data from other healthcare jurisdictions that could be generalizable to the Canadian context.

Methods: We conducted a systematic review of the published peer-reviewed literature. We included studies from Organization for Economic Cooperation and Development countries, excluding the U.S., published in English since January 2009.

Results: From 165 abstracts identified in our initial search, 18 studies were ultimately included for analysis. This included one Canadian-based study reporting costs in Canadian dollars, all related to second-line treatments. The other studies were primarily from Europe, reporting costs in Euros or U.K. pounds. There were no studies reporting costs for first-line treatments. Gaps in costs for select second-line and third-line treatments recommended by the CUA were also identified.
Conclusions: Canadian-specific cost data for OAB treatments published in the peer-reviewed literature is limited to a single study reporting costs for only a few second-line treatments sourced from a single province over 10 years ago. Cost data from other healthcare jurisdictions are available, but the generalizability of costs associated with third-line treatments is questionable.

Introduction
Idiopathic overactive bladder (OAB) is a chronic condition involving the perceived or real urge to urinate, that is not determined to be caused by neurologic, hormonal or metabolic disruption. In general, OAB involves abnormal contractions of the detrusor muscle during the normally relaxed storage phase of micturition, which causes bladder urgency and frequent voiding. There are several pathophysiologies for OAB: lifestyle, pelvic floor muscular weakness, incorrect function of urinary system, and comorbidities with pre-existing health conditions.

The Canadian Urologic Association (CUA) has established treatment guidelines for OAB that include several lines of treatment varying in terms of their intensity. First line treatments include behavioural modifications and lifestyle treatments, second line treatments involve the use of pharmaceutical drugs, and third line treatments involve interventional procedures. For those with severe symptoms refractory to these treatments, alternatives are suggested, including indwelling catheters, augmentation cystoplasty, and urinary diversion.

It is important to understand how these treatments are reviewed, approved, and recommended in Canada for inclusion in drug formularies or lists of medically insured benefits. Understanding these processes and the information upon which these decisions are made can help shape an agenda for future research in the development of new treatments for OAB.

For new pharmaceuticals, there is a centralized process for reviewing and recommending new drugs for federal, provincial, and territorial drug plans. This process is undertaken largely by The Canadian Agency for Drugs and Technologies in Health (CADTH). For non-drug technologies (NDTs), the process is more decentralized, with each province – and in some cases health authorities or hospitals – having their own unique list of organizations/boards/committees responsible for reviewing and recommending new NDTs. For example, in Alberta, new NDTs for surgery are conducted by the Evidence Decision Support Program (EDSP) within the province’s single health region, Alberta Health Services.

Regardless of whether it is a new pharmaceutical or NDT, evidence syntheses, also referred to as health technology assessments (HTA), largely inform decisions with respect to recommending a new treatment. HTAs weigh the clinical effectiveness and safety of the new treatment against its costs. HTAs will often compare the cost-effectiveness of new treatments relative to older treatments. For example, CADTH reviewed the clinical- and cost-effectiveness of intravesical botulinum toxin to treat OAB compared to lifestyle modifications.
retraining, use of anticholinergic drugs, and placebo. Rarely do these agencies collect primary data for themselves. For the most part, data regarding clinical benefits, harms, and costs are synthesized from published peer-reviewed studies.

The studies from which cost data are sourced for HTA can have a great deal of influence on the interpretation of a new treatment’s cost-effectiveness. CADTH prefers that the cost data be sourced from the jurisdiction in which the new treatment is being considered. For example, if a new treatment is being considered for Canada, then ideally the cost data would come from Canada. If these data do not exist, CADTH recommends using data sourced from a closely generalizable jurisdiction, and preferentially a single jurisdiction for all costs.

The purpose of this study is to identify peer-reviewed studies that include cost data for OAB treatments. Our primary aim is to identify published studies that report Canadian-specific cost data. If no such studies can be identified, our secondary aim is to identify studies that report cost data from other healthcare jurisdictions that could be generalizable to the Canadian context. The results from this study will help reveal the shortcomings in our current knowledge of OAB treatment costs, areas that are in need of future research and reporting, and the ultimate improvement of HTAs for future urologic treatments for OAB.

Methods
We conducted a systematic review of the published peer-reviewed literature regarding the costs associated with treating OAB. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), and a completed PRISMA checklist was provided with the submission of this manuscript.

Search strategy
We focused our literature search on studies reporting data from OECD (Organization for Economic Cooperation and Development) countries, excluding the United States. Given the United States’ unique health care system, we did not think that costs from this jurisdiction would be generalizable to the Canadian context, thus not relevant for future HTAs. A trained medical librarian assisted in developing the search strategy for Ovid Medline and Embase databases. The list of keywords used, and an example of the search strategy, is included as Appendix 1. The search was executed between August and September 2020. The search was limited to studies that were published in English since January 2009. This date restriction was used to limit the search to more current estimate of costs associated with contemporary OAB treatment and management plans. The last day of the literature searching was September 9, 2020.

The search results were uploaded and reviewed using Covidence. Two reviewers (DV and CB) independently screened the abstracts resulting from the searches. Abstracts were included for full text review if they listed monetary costs associated with OAB for patients aged 18 years or older. Abstracts were excluded if they: 1) focused on neurogenic detrusor overactivity (NDO); 2) primarily reported cost data from the U.S.; or 3) were editorials, commentaries, review articles, letters, conference transcripts, posters. If the eligibility could not be determined from the abstract, the full text was reviewed to make the determination.

The primary data sources used in this study were peer-reviewed journals, government reports, health technology assessment reports, and specialized literature databases. The search strategy was designed to identify studies that reported cost data for OAB treatments. The results from this study will help reveal the shortcomings in our current knowledge of OAB treatment costs, areas that are in need of future research and reporting, and the ultimate improvement of HTAs for future urologic treatments for OAB.
be determined by from the abstract, the reviewers aired on the side of caution and included it for full text review. Discrepancies were compared and resolved by a third reviewer (RTC). Because the search was looking for initial input costs, there was low chance for bias affecting the observations. However, the sources of all costs were noted, when available, to help identify the chance of bias.

Data summary
DV and CB abstracted the data from the articles that met the inclusion and exclusion criteria. Two Microsoft Excel spread sheet were used, one to collect study details (jurisdiction, methods, intervention(s), sample size, etc.) and another to collect costs. Costs associated with treating OAB were recorded exactly as found in original studies. Where costs were presented as existing within a range of two numbers, the average value of the high and low values was used. The dosage or unit of analysis were also recorded.

To allow informative cost comparison between different years and countries, all costs were converted into January 1, 2020 Canadian dollars. These rates were calculated upon historic exchange and inflation rates of the original costs. If only the year of the costs were given and no date specified, the costs were then converted to the January 1st rate of that calendar year. Where costs covered a two-year range, the earlier year was selected for the calculation of costs. The online historical currency converters fx-rate.net 14, freecurrencyrates.com 15 and the Bank of Canada historical Canadian inflation converter 16 were used for the conversion of currencies.

We summarized the results by lines of treatment recommended in the CUA guidelines on OAB. These results first identify those studies that report Canadian costs, then costs from other jurisdictions. When different studies report costs from the same source, we report data from only the most recent study.

Results
The search strategy yielded 165 abstracts, from which 63 were selected for full-text review. Primary reasons for exclusion included: no cost data reported or not reported for a specific treatment (e.g., reported as general antimuscarinics drugs), U.S.-based studies, not reporting costs in a comparable unit (e.g., for an unspecified “cycle” of treatment), focused on NDO, and reviews/ commentaries. A total of 18 unique studies met the criteria for inclusion in our analysis. Figure 1 provides the PRISMA flow chart.

Study Characteristics
Table 1 provides the details of the 18 studies included in the analysis. The majority (n = 12; 67%) were published between 2009 and 2014. There was one study that included data from Canada. The remaining studies came from the United Kingdom (U.K.) (n = 7; 39%), Spain (n = 5; 28%), and Italy (n = 3; 17%). Similarly, there was one study that reported costs in Canadian Dollars. The others reported costs in Euros (n = 10; 56%), British Pounds (n = 6; 33%), and Japanese Yen (n = 1; 6%).
The majority of included studies (n = 13; 72%) reported cost data related to the use of pharmaceutical drugs. Cost data related to the use of Botulinum toxin A were reported in 6 (33%) studies, although one (study ID #12) did not report a dosage unit and was therefore excluded for this particular treatment. Four (22%) studies reported cost data related to sacral neuromodulation.

First-line treatment
The CUA guidelines recommends behavioural therapy (i.e., bladder training and pelvic floor muscle therapy) and lifestyle changes (i.e., fluid and caffeine intake, diet management, weight loss) as first line treatments for OAB. Our search did not identify any studies reporting costs associated with these treatments, either from Canada or from any other jurisdiction.

Second-line treatment
As second line treatments, the CUA guidelines recommends antimuscarinics (i.e., oxybutynin, immediate release, extended release, transdermal; tolterodine, immediate release, extended release; darifenacin; solifenacin; propiverine; fesoterodine) and beta-3 adrenoceptor agonist (i.e., mirabegron). The costs associated with second line treatments extracted from the included studies are provided in Table 2. There were no studies that reported costs related to propiverine.

There were 4 (22%) studies that reported costs for oxybutynin. A single study reported Canadian costs in 2010 dollars, $0.20 for 5 mg of immediate release ($0.23 in 2020 terms). The remaining studies were all based in the U.K, and reported costs in the U.K. Pound taken from the British National Formulary. The most recent, from 2015, included costs for both 5 mg of immediate and extended release ($0.14 and $0.90 in 2020 Canadian dollars, respectively).

There were 9 (50%) studies that reported costs for tolterodine. Again, one study reported Canadian costs in 2010 dollars ($2.13 in 2020 terms). Four (22%) studies reported costs in Euros from six different countries, between 2006 and 2012 (range: $1.51 - $4.39 in 2020 Canadian dollars). Four (22%) studies reported costs in U.K. Pound, the most recent from 2015 ($1.80 and $0.18 in 2020 Canadian dollars for extended and immediate release, respectively). One study reported costs in 2016 Japanese Yen ($2.32 in 2020 Canadian dollars).

Two (11%) studies reported costs for darifenacin. Both reported costs in U.K. Pound, the most recent in 2015 ($1.85 in 2020 Canadian dollars for 15 mg and $1.78 in 2020 Canadian dollars for 7.5 mg). There were no studies reporting Canadian costs.

There were 9 (50%) studies that reported costs for solifenacin. One study reported Canadian costs in 2010 dollars ($1.92 in 2020 terms). Four (22%) studies reported costs in U.K. Pound, the most recent in 2015 ($2.35 in 2020 Canadian dollars and $1.80 in 2020 Canadian dollars for 10 mg and 5 mg, respectively). Four (22%) studies reported Euros from seven different countries, the most recent 2012 (range: $2.20 - $4.07 in 2020 Canadian dollars).

There were 5 (28%) studies that reported fesoterodine. Two (11%) of these reported costs in U.K. Pound, the most recent from 2015 ($1.80 in 2020 Canadian dollars). Three (17%)
reported costs in Euros from 2 different countries, the most recent in 2015 (range: $2.10 - $3.81 in 2020 Canadian dollars). There were no studies reporting Canadian costs.

Three (17%) studies reported costs related to mirabegron. Two (11%) of these reported costs in U.K. Pound, the most recent from 2015 ($1.90 in 2020 Canadian dollars). One study, from Spain, reported costs in 2015 Euros ($2.13 in 2020 Canadian dollars). One reported 2016 Japanese Yen ($2.44 in 2020 Canadian dollars). There were no studies reporting Canadian costs.

Third-line treatment
For third line treatments, the CUA guidelines recommends OnabotulinumtoxinA, peripheral tibial nerve stimulation (PTNS), and sacral neuromodulation (SNM). The costs associated with third line treatments extracted from the included studies are provided in Table 3. There were no studies that reported Canadian costs, nor were there any studies reporting costs associated with PTNS.

The heterogeneity with which these treatments were described in the respective studies makes it a difficulty to directly compare them across countries. For example, most studies reported costs for a generic “procedure”, without a full description of what was included in that category. Consequently, the costs, particularly for SNM, vary widely.

Discussion
This study aimed to understand the availability of Canadian cost data for OAB treatment. In the absence of data from Canada, we sought to identify the most recently published cost data from healthcare jurisdictions that are generalizable to the Canadian context. Using the CUA guidelines for the management of OAB, we characterized treatments by first, second, and third lines.

A single Canadian study reporting treatments – all related to second line – in Canadian dollars was identified. This study was published over a decade ago and is based on data sourced from a single province, Ontario. Moreover, these costs were all related to antimuscarinics, specifically oxybutynin, tolterodine, and solifenacin. There were no published cost data related to beta-3 adrenoceptor agonist. Nor did we find any published Canadian cost data related to first-or third-line treatments.

The results from our study demonstrate the deficiencies in our understanding of Canadian-specific costs for OAB treatments. These deficiencies limit the ability to conduct HTAs because cost-effectiveness analyses of new and old treatments require accurate cost data. This impairs the introduction of new treatments for OAB to provincial drug formularies or the NDTs that are covered by provincial health insurance programs. Ultimately, this reduces the choice of OAB treatments for clinicians and their patients.

Canadian agencies conducting HTAs, like CADTH, are willing to consider cost data from other jurisdictions, provided that they are generalizable to the Canadian context. The results from this study demonstrate that there are several studies reporting OAB treatment cost data from a number of countries with publicly-funded healthcare systems, mostly from Europe. Although,
even here we have identify gaps in the published research. Most notably, that there are no cost data published for first line treatments.

For second line treatments, the most recently published cost data are from 2015, all sourced from the U.K. There are costs data published for all second line treatments recommended by the CUA, save for propiverine. The dosages reported are aligned with those recommended by the CUA, so the use of these data in cost-effectiveness research should be straightforward.

For third line treatments, cost data from 2014 for onabotulinumtoxinA have been published from several European countries. For SNS, the most recent data comes from the U.K. in 2012. There were no studies for PTNS with useable cost data. The applicability of these data to the Canadian context is not as simple as it is for second line treatment, which is strictly comprised of the cost of the drug. Third line treatments can include physician fees for procedures, disposables, hospital recovery, specialized nursing costs, revisions, etc. These may not be translatable to the Canadian context.

This study demonstrates the need for more rigorous Canadian-specific research into OAB treatments that reports cost data from reliable sources. These studies need not come from clinical trials, but come from “real world” data taken from administrative data maintained by provincial health authorities. In Canada, both Ontario and Alberta collect microcosting data that would provide the granularity for reporting treatment costs, particularly as they relate to third line treatments. The field of urology should take it upon itself to develop a research agenda that would systematically address the gaps in Canadian-specific cost gaps identified through this study.

There are several limitations to this study that should be noted. First, the search was limited to publications that were written in English. We are aware of work by le Institut national d'excellence en santé et en services sociaux that has reported the costs associated with mirabegron and OnabotulinumtoxinA. However, these works are not formally published in peer-reviewed journals and are written in French, and therefore fall out of the scope of this systematic review. There may be French studies from Quebec that were excluded. Second, our search strategy did not include grey literature. This was intentional as we wanted to maintain a manageable number of studies for review and limit the chance for bias in our results from costs data that may not have been peer-reviewed. Finally, we limited the results to only those treatments recommended by the CUA. We identified cost data for other treatments (e.g., trospium) but refrained from reporting them to keep within the boundaries of the CUA’s own evidence-based evaluation.

Conclusions
Canadian-specific cost data for OAB treatments published in the peer-reviewed literature is limited. What is available is for second line treatment, sourced from a single province, and dated. Cost data from other healthcare jurisdictions similar to the Canadian context is available, but the
applicability of costs associated with third line treatments is questionable. A systematic and coordinated effort is needed to fill the gaps in our cost knowledge in order to facilitate HTAs for future OAB treatments.
References

1. Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75(6):988-1000.
2. Shah MB, Weiss JP. Medical Causes of Overactive Bladder. Curr Bladder Dysfunct Rep. 2013;8(1):51-56.
3. Marcelissen T, Anding R, Averbeck M, Hanna-Mitchell A, Rahnama’i S, Cardozo L. Exploring the relation between obesity and urinary incontinence: Pathophysiology, clinical implications, and the effect of weight reduction, ICI-RS 2018. Neurourol Urodyn. 2019;38:S18–S24.
4. Corcos J, Przydacz M, Campeau L, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142-E173. doi:10.5489/cuaj.4586
5. Stafinski T, Deber R, Rhainds M, et al. The Introduction of New Non-Drug Health Technologies into Canadian Healthcare Institutions: Opportunities and Challenges. Healthc Policy. 2019;15(1):95-106. doi:10.12927/hcpol.2019.25935
6. Battista RN, Côté B, Hodge MJ, Husereau D. Health technology assessment in Canada. Int J Technol Assess Health Care. 2009;25(SUPPL.S1):53-60. doi:10.1017/S0266462309090424
7. Stafinski T, Deber R, Rhainds M, et al. Decision-Making on New Non-Drug Health Technologies by Hospitals and Health Authorities in Canada. Healthc Policy. 2019;15(1):82-94. doi:10.12927/hcpol.2019.25936
8. Evidence Decision Support Program. New Health Technology Request. Published 2021. Accessed June 10, 2021. https://albertahealthservices.ca/scns/Page12978.aspx
9. Martin J, Polisena J, Dengukuri N, Rhainds M, Sampietro-Colom L. Local health technology assessment in Canada: Current state and next steps. Int J Technol Assess Health Care. 2016;32(3):175-180. doi:10.1017/S0266462316000210
10. Ho C, Visintini S. Intravesical Botulinum Toxin for Adults with Non-Neurogenic Bladder Conditions: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines.; 2018. https://www.ncbi.nlm.nih.gov/pubmed/30329252%0Ahttps://www.ncbi.nlm.nih.gov/books/NBK532207/
11. CADTH. Guidelines for the Economic Evaluation of Health Technologies: Canada. 4th ed. CADTH; 2017. doi:10.2307/324667
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(7716):332-336. doi:10.1136/bmj.b2535
13. Covidence systematic review software. http://www.covidence.org/
14. Exchange Rate Database. Historical rates.
15. Free Currency Rates. Online Currency Converter.
16. Bank of Canada. Inflation Calculator.
17. Husereau D, Nason E, Ahuja T, Nikaï E, Tsakonas E, Jacobs P. Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries. Int J Technol Assess Health Care. 2019;35(3):181-188. doi:10.1017/S0266462319000291
18. Clement Nee Shrive FM, Ghali WA, Donaldson C, Manns BJ. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches. Health Econ. 2009;18(4):377-388. doi:10.1002/hec.1363

19. Akhtar AO, Martin J, Zaric GS, Si F, Hutnik CML, Hodge WG. A comparison of clinical trial and model-based cost estimates in glaucoma – The case of repeat laser trabeculoplasty In Ontario. J Hosp Adm. 2017;6(3):46. doi:10.5430/jha.v6n3p46

20. Institut national d’excellence en santé et en services sociaux. Excerpt from the Notice to the Minister on myrbetriq. Published 2014. Accessed August 9, 2021. https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/myrbetriq-2556.html?DemandePluginController%5Bonglet%5D=0&cHash=00ffdd9fa17d8655f8b588589587dc1

21. Institut national d’excellence en santé et en services sociaux. Extrait de l’avis au ministre sur Botox (Traitement de l’hyperactivité vésicale). Published 2019. Accessed August 9, 2021. https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/botox-hyperactivite-vesicale-idio(pathique-4788.html

22. Hakkaart L, Hakkaart L, Verboom P, et al. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol. 2009;41(2):293-298. doi:10.1007/s11255-008-9448-2

23. Pradelli L, Iannazzo S. Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. J Med Econ. 2009;12(1):25-35. doi:10.3111/13696990902767800

24. Milsom I, Axelsen S, Kulseng-Hansen S, Mattiasson A, Nilsson CG, Wickstrom J. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obs Gynecol Scand. 2009;88(6):693-699. doi:10.1080/00016340902849738

25. Herschorn S, Vicente C, Piwko C. Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. J Med Econ. 2010;13(3):508-515. doi:10.3111/13696998.2010.509244

26. Leong RK, de Wachter SGG, Joore MA, van Kerrebroeck PE V. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int. 2011;108(4):558-564. doi:10.1111/j.1464-410x.2010.09905.x

27. Arlandis S, Castro D, Errando C, et al. Cost-Effectiveness of Sacral Neuromodulation Compared to Botulinum Neurotoxin A or Continued Medical Management in Refractory Overactive Bladder. Value Heal. 2011;14(2):219-228. doi:10.1016/j.jval.2010.08.006

28. Arlandis-Guzman S, Errando-Smet C, Trocio J, Arumi D, Rejas J. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. BMC Urol. 2011;11(1):9. doi:10.1186/1471-2490-11-9

29. Verheggen BG, Lee R, Lieuw On MM, et al. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder. J Med Econ. 2012;15(3):586-600. doi:10.3111/13696998.2012.666511
30. Hart WM, Abrams P, Munro V, Retsa P, Nazir J. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom. J Med Econ. 2013;16(10):1246-1254. doi:10.3111/13696998.2013.829079

31. Nazir J, Hart WM. The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service. J Med Econ. 2014;17(6):408-414. doi:10.3111/13696998.2014.910217

32. Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ. Cost Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland. Clin Drug Investig. 2014;34(5):297-307. doi:10.1007/s40261-014-0178-1

33. Bertapelle MP, Bertapelle MP, Vottero M, et al. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol. 2015;33(8):1109-1117. doi:10.1007/s00345-014-1401-7

34. Nazir MSc J, Maman MSc K, Neine MSc M-E, et al. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom. Value Heal. 2015;18(6):783-790. doi:10.1016/j.jval.2015.05.011

35. Freemantle N, Khalaf K, Loveman C, et al. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales. Eur J Heal Econ. 2016;17(7):911-921. doi:10.1007/s10198-015-0737-2

36. Ruff L, Bagshaw E, Aracil J, Velard M-E, Pardhanani G, Hepp Z. Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe. J Med Econ. 2016;19(12):1107-1115. doi:10.1080/13696998.2016.1199430

37. Angulo JC, Sánchez-Ballester F, Peral C, et al. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. Spanish Urol (Actas Urológicas Españolas, English Ed. 2016;40(8):513-522. doi:10.1016/j.acuroe.2016.07.006

38. Nazir J, Berling M, McCrea C, et al. Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK. Pharmacoecon Open. 2017;1(1):25-36. doi:10.1007/s41669-017-0011-x

39. Yamanishi Y, Yamanishi T, Tajima H, Ikeda S. Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment? Int J Urol. 2018;25(10):863-870. doi:10.1111/iju.13764
Figures and Tables

Fig. 1. PRISMA flow diagram of records identified, included, and excluded.

Records identified through database searching (n = 165)

Additional records identified through other sources (n = 0)

Records after duplicates removed (n = 13)

Records screened (n = 152)

Records excluded (n = 89)

Full-text articles assessed for eligibility (n = 63)

Full-text articles excluded, with reasons (n = 45)
21 - No cost data
9 - U.S.-based
7 - Does not report costs at a comparable unit
2 - Not OAB
1 - Does not report specific treatment
1 - Conference poster
1 - Journal index
1 - Protocol
1 - Retracted article
1 - No author reply

Studies included in the synthesis (n = 18)
Table 1. Details on studies selected for full-text review

| Study ID (reference) | Publication year | Country / countries | Currency       | Price year | Included treatments                                      |
|----------------------|------------------|---------------------|----------------|------------|---------------------------------------------------------|
| 1 (22)               | 2009             | U.K.                | British Pound | 2004       | Solifenacin                                             |
| 2 (23)               | 2009             | Italy               | Euro           | 2009       | Solifenacin, tolterodine                                 |
| 3 (24)               | 2009             | Denmark, Finland, Norway, Sweden | Euro | 2006       | Solifenacin, tolterodine                                 |
| 4 (25)               | 2010             | Canada              | Canadian Dollars | 2009       | Oxybutynin, solifenacin                                  |
| 5 (26)               | 2010             | The Netherlands     | Euro           | 2012       | Botulinum toxin A, sacral neuromodulation               |
| 6 (27)               | 2011             | Spain               | Euro           | 2008       | Botulinum toxin A, sacral neuromodulation               |
| 7 (28)               | 2011             | Spain               | Euro           | 2010       | Fesoterodine, solifenacin, tolterodine                  |
| 8 (29)               | 2012             | U.K.                | British Pound | 2010       | Tamsulosin, tolterodine                                 |
| 9 (30)               | 2013             | U.K.                | British Pound | 2010       | Oxybutynin, solifenacin, tolterodine                    |
| 10 (31)              | 2014             | Germany             | Euro           | 2012       | Solifenacin, trospium                                   |
| 11 (32)              | 2014             | Finland, Spain      | Euro           | 2012       | Fesoterodine, tolterodine                               |
| 12 (33)              | 2014             | Italy               | Euro           | 2011       | Botulinum toxin A, sacral neuromodulation               |
| 13 (34)              | 2015             | U.K.                | British Pound | 2012       | Botulinum toxin A*, darifenacin, fesoterodine, mirabegron, oxybutynin, solifenacin, tolterodine, trospium |
| 14 (35)              | 2015             | U.K.                | British Pound | 2012       | Botulinum toxin A, sacral neuromodulation               |
| 15 (36)              | 2016             | France, Germany, Italy, Spain, U.K. | Euro | 2014       | Botulinum toxin A                                       |
| 16 (37)              | 2016             | Spain               | Euro           | 2011       | Fesoterodine, mirabegron                                |
| 17 (38)              | 2017             | U.K.                | British Pound | 2015       | Darifenacin, flavoxate, fesoterodine, mirabegron, oxybutynin, solifenacin, tolterodine, trospium |
| 18 (39)              | 2018             | Japan               | Japanese Yen   | 2016       | Mirabegron, tolterodine                                 |
Table 2. Most recent costs reported for second-line overactive bladder treatments, by jurisdiction

| Treatment | Study ID | Country  | Original currency | Dosage unit | Source                                          | Reported cost | Converted cost (CAN 2020) |
|-----------|----------|----------|-------------------|-------------|-------------------------------------------------|---------------|--------------------------|
| Oxybutine | 4        | Canada   | Canadian Dollars - 2010 | 5mg (IR)    | Ontario Drug Benefit Formulary (2009)          | 0.20          | 0.23                     |
|           | 17       | U.K.     | U.K. Pound - 2015   | 5mg (ER)    | British National formulary (2016)             | 0.46          | 0.90                     |
|           | 17       | U.K.     | U.K. Pound - 2015   | 5mg (IR)    | British National formulary (2016)             | 0.07          | 0.14                     |
| Tolterodine | 4  | Canada   | Canadian Dollars - 2010 | 4mg         | Ontario Drug Benefit Formulary (2009)          | 1.82          | 2.13                     |
|           | 2        | Italy    | Euro - 2007         | 4mg         | Italian National Formulary (2007)             | 2.34          | 4.39                     |
|           | 3        | Sweden   | Euro - 2006         | 4mg (SR)    | Not referenced                                | 1.48          | 2.54                     |
|           | 3        | Norway   | Euro - 2006         | 4mg (SR)    | Not referenced                                | 1.42          | 2.44                     |
|           | 3        | Denmark  | Euro - 2006         | 4mg (SR)    | Not referenced                                | 1.77          | 3.04                     |
|           | 11       | Finland  | Euro - 2012         | 4mg (ER)    | Not referenced                                | 1.42          | 2.08                     |
|           | 11       | Spain    | Euro - 2012         | 4mg (ER)    | Not referenced                                | 1.03          | 1.51                     |
|           | 17       | U.K.     | U.K. Pound - 2015   | 4mg (ER)    | British National formulary (2016)             | 0.92          | 1.80                     |
|           | 17       | U.K.     | U.K. Pound - 2015   | 4mg (IR)    | British National formulary (2016)             | 0.09          | 0.18                     |
## Costs associated with OAB treatment

|   | Country | Currency | Year | Dosage  | Source | Cost (local currency) | Cost (local currency) |
|---|---------|----------|------|---------|--------|-----------------------|-----------------------|
| 4 | Canada  | Canadian Dollars - 2010 | 5 mg | Not referenced | Astellas Pharma Canada Inc. | 1.64 | 1.92 |
| 2 | Italy   | Euro - 2007 | 5 mg | | Italian National Formulary (2007) | 2.17 | 4.07 |
| 3 | Sweden  | Euro - 2006 | 5 mg | | Not referenced | 1.36 | 2.34 |
| 3 | Sweden  | Euro - 2006 | 10 mg | | Not referenced | 1.65 | 2.83 |
| 3 | Norway  | Euro - 2006 | 5 mg | | Not referenced | 1.28 | 2.20 |
| 3 | Norway  | Euro - 2006 | 10 mg | | Not referenced | 1.51 | 2.59 |
| 3 | Finland | Euro - 2006 | 5 mg | | Not referenced | 1.79 | 3.07 |
| 3 | Finland | Euro - 2006 | 10 mg | | Not referenced | 1.64 | 2.82 |
| 3 | Denmark | Euro - 2006 | 5 mg | | Not referenced | 1.46 | 2.51 |
| 3 | Denmark | Euro - 2006 | 10 mg | | Not referenced | 1.82 | 3.13 |
| 7 | Spain   | Euro - 2010 | 5 mg | Portalfarma; General Council of Provincial Pharmacy Chambers (2009) | 1.67 | 2.95 |
| 7 | Spain   | Euro - 2010 | 10 mg | Portalfarma; General Council of Provincial Pharmacy Chambers (2009) | 2.67 | 4.72 |
| 10 | Germany | Euro - 2012 | 5 mg | Data from various German sickness funds | 1.66 | 2.43 |
| 10 | Germany | Euro - 2012 | 10 mg | Data from various German sickness funds | 1.97 | 2.89 |
| 17 | U.K.   | U.K. Pound - 2015 | 5 mg | British National formulary (2016) | 0.92 | 1.80 |
| 17 | U.K.   | U.K. Pound - 2015 | 10 mg | British National formulary (2016) | 1.20 | 2.35 |
| 11 | Finland | Euro - 2012 | 4 mg | Not referenced | 1.43 | 2.10 |
| 11 | Finland | Euro - 2012 | 8 mg | Not referenced | 1.57 | 2.30 |
| 16 | Spain   | Euro - 2015 | 4 mg | Portalfarma; General Council of Provincial Pharmacy Chambers (2015) | 1.60 | 2.44 |
## Costs associated with OAB treatment

| Country | Region    | Currency     | Year   | Dose | Source                                                                 | Price  | Unit |
|---------|-----------|--------------|--------|------|------------------------------------------------------------------------|--------|------|
| Spain   |           | Euro - 2015  | 8 mg   |      | Portafarma; General Council of Provincial Pharmacy Chambers (2015)     | 2.50   |      |
| U.K.    |           | U.K. Pound - 2015 | 4/8 mg |      | British National formulary (2016)                                    | 0.92   |      |
| Spain   |           | Euro - 2015  | 50 mg  |      | Portafarma; General Council of Provincial Pharmacy Chambers (2015)     | 1.40   |      |
| U.K.    |           | U.K. Pound - 2015 | 50 mg |      | British National formulary (2016)                                    | 0.97   |      |
| Japan   |           | Japanese Yen - 2016 | 50 mg |      | Not referenced                                                        | 200.00 |      |

**Mirabegron**

| Country | Region    | Currency     | Year   | Dose | Source                                                                 | Price  | Unit |
|---------|-----------|--------------|--------|------|------------------------------------------------------------------------|--------|------|
| Spain   |           | Euro - 2015  | 50 mg  |      | Portafarma; General Council of Provincial Pharmacy Chambers (2015)     | 1.40   |      |
| U.K.    |           | U.K. Pound - 2015 | 50 mg |      | British National formulary (2016)                                    | 0.97   |      |
| Japan   |           | Japanese Yen - 2016 | 50 mg |      | Not referenced                                                        | 200.00 |      |
Table 3. Most recent costs reported for third-line overactive bladder treatments by jurisdiction

| Treatment             | Study ID | Country          | Original currency | Explanation                          | Dosage/unit | Source                                      | Reported Cost | Converted cost (CAN 2020) |
|-----------------------|----------|------------------|-------------------|--------------------------------------|-------------|---------------------------------------------|---------------|--------------------------|
| Onabotulinumtoxin A   | 5        | The Netherlands  | Euro - 2008       | Pre procedure                        | Per event   | Healthcare Institute Netherlands            | 290.00        | 508.78                   |
|                       |          |                  |                   | Procedure (including 200 U injection) | Per event   | Healthcare Institute Netherlands            | 1564.00       | 2743.88                  |
|                       | 6        | Spain            | Euro - 2008       | Pre procedure                        | Per event   | e-Salud database; Spanish Ministry of Health| 572.00        | 1003.52                  |
|                       |          |                  |                   | Procedure                            | Per event   | e-Salud database; Spanish Ministry of Health| 1192.00       | 2091.24                  |
|                       | 12       | Italy            | Euro - 2011       | Pre procedure                        | Per event   | Not referenced                              | 217.07        | 328.69                   |
|                       |          |                  |                   | Procedure (including 100 U injection) | 100 U       | Not referenced                              | 1654.99       | 2505.99                  |
|                       | 15       | France           | Euro - 2014       | Injection                            | 100 U       | Allergan Ltd (2015)                         | 216.10        | 340.75                   |
|                       |          |                  |                   | Procedure                            | Inpatient   | Allergan Ltd (2014)                         | 2169.28       | 3420.52                  |
|                       |          |                  |                   | Procedure                            | Day-case    | Referentiel de couts MCO. ScanSante, 2012   | 754.00        | 1188.91                  |
|                       |          |                  |                   | Procedure                            | Outpatient  | Study                                       | 213.00        | 335.86                   |
|                       | 15       | Germany          | Euro - 2014       | Injection                            | 100 U       | Allergan Ltd (2015)                         | 406.87        | 641.55                   |
|                       |          |                  |                   | Procedure                            | Inpatient   | Allergan Ltd (2015)                         | 2700.00       | 4257.36                  |
## Costs associated with OAB treatment

| Country     | Procedure Type | Year | Cost 1 | Cost 2 |
|-------------|----------------|------|--------|--------|
| Germany     | Procedure Day-case | 2014 | 850.00 | 1340.28 |
| Germany     | Procedure Outpatient | 2014 | 109.00 | 171.87 |
| Italy       | Injection 100 U | 2014 | 214.54 | 338.29 |
| Italy       | Procedure Inpatient | 2014 | 1075.00 | 1695.06 |
| Italy       | Procedure Day-case | 2014 | 404.66 | 638.07 |
| Italy       | Procedure Outpatient | 2014 | 406.66 | 641.22 |
| Spain       | Injection 100 U | 2014 | 205.03 | 323.29 |
| Spain       | Procedure Inpatient | 2014 | 875.31 | 1380.19 |
| Spain       | Procedure Day-case | 2014 | 162.97 | 256.97 |
| Spain       | Procedure Outpatient | 2014 | 162.97 | 256.97 |
| U.K.        | Injection 100 U | 2014 | 195.16 | 307.73 |
| U.K.        | Procedure Inpatient | 2014 | 545.62 | 860.33 |
| U.K.        | Procedure Day-case | 2014 | 275.33 | 434.14 |
| U.K.        | Procedure Outpatient | 2014 | 275.33 | 434.14 |
| The Netherlands | Pre procedure | 2008 | 278.00 | 487.72 |

### Sacral neuromodulation

The Netherlands | Euro - 2008 | Pre procedure | Per event | Healthcare Institute Netherlands | 278.00 | 487.72

---

© 2021 Canadian Urological Association
## Costs associated with OAB treatment

| Country | Year | Service Description | Event | Healthcare Institute | Cost 2008 | Cost 2011 |
|---------|------|---------------------|-------|-----------------------|------------|-----------|
| 5 The Netherlands | 2008 | First-stage tined lead procedure | Per event | Healthcare Institute Netherlands | 3445.00 | 6043.91 |
| 5 The Netherlands | 2008 | Second-stage tined lead procedure | Per event | Healthcare Institute Netherlands | 9150.00 | 16 052.76 |
| 5 The Netherlands | 2008 | Surgical revision | Per event | Healthcare Institute Netherlands | 2590.00 | 4543.90 |
| 5 The Netherlands | 2008 | Surgical removal | Per event | Healthcare Institute Netherlands | 11 448.00 | 20 084.37 |
| 6 Spain | 2008 | Test pre-procedure | Per event | Medtronic | 558.00 | 978.96 |
| 6 Spain | 2008 | Test | Per event | Medtronic | 2781.00 | 4878.99 |
| 6 Spain | 2008 | Procedure | Per event | Medtronic | 9734.00 | 17 077.33 |
| 12 Italy | 2011 | Test pre-procedure | Per event | Not referenced | 213.65 | 323.51 |
| 12 Italy | 2011 | Test and implanted devices | Per event | Not referenced | 5622.35 | 8513.36 |
| 12 Italy | 2011 | Implantation pre-procedure costs | Per event | Not referenced | 104.59 | 158.37 |
| 12 Italy | 2011 | Implantation including implanted devices | Per event | Not referenced | 9433.34 | 14 283.96 |
| 12 Italy | 2011 | Lead repositioning for migration or decreased clinical response including implanted devices | Per event | Not referenced | 5873.03 | 8892.94 |
| 12 Italy | 2011 | Lead replacement for breaking including implanted devices | Per event | Not referenced | 5684.37 | 8607.27 |
| 12 Italy | 2011 | Generator repositioning | Per event | Not referenced | 2674.69 | 4050.02 |
| 12 | Italy | Euro - 2011 | Lead explantation | Per event | Not referenced | 724.55 | 1097.11 |
| 14 | U.K. | Pound - 2012 | Physician visit follow up | Per Visit | National tariff information workbook (2014-2015) | 319.00 | 563.00 |
| 14 | U.K. | Pound - 2012 | Removal of temporary electrodes | Per event | Study | 1166.00 | 2,057.87 |
| 14 | U.K. | Pound - 2012 | First-stage implant | Per event | Study | 8641.00 | 15 250.50 |
| 14 | U.K. | Pound - 2012 | Battery replacement | Per event | Study | 6623.00 | 11688.93 |
| 14 | U.K. | Pound - 2012 | Device explant | Per event | Study, OPCS classification of interventions and procedures | 923.00 | 1629.00 |
| 14 | U.K. | Pound - 2012 | Surgical revision | Per event | Study, Department of Health: NHS reference costs | 592.00 | 1044.82 |
Appendix 1

EMBASE Classic <2009 to present> Search date: 9 June 2020

| Number | Searches                                           | June 9 Results |
|--------|----------------------------------------------------|----------------|
| 1      | Urinary Bladder, Overactive/                       | 4482           |
| 2      | exp "Costs and Cost Analysis"/                    | 347462         |
| 3      | 1 and 2                                            | 143            |
| 4      | limit 3 to yr="2009 -Current"                      | 55             |
| 5      | limit 4 to english language                        | 53             |

| Number | Searches                                           | June 9 Results |
|--------|----------------------------------------------------|----------------|
| 1      | Urinary Bladder, Overactive/                       | 4482           |
| 2      | exp "Costs and Cost Analysis"/                    | 347462         |
| 3      | 1 and 2                                            | 143            |
| 4      | limit 3 to yr="2009 -Current"                      | 55             |
| 5      | limit 4 to english language                        | 53             |